Voxsanity

Who may be able to join

Who might be able to join this trial:

You have been diagnosed with breast cancer that has spread to other parts of the body or has come back, confirmed by a tissue sample (biopsy).
You are 18 years of age or older.
Your breast cancer is one of the following types: triple-negative (TNBC), HER2-positive, or hormone receptor-positive.
You have previously been treated with a type of cancer drug called an antibody-drug conjugate (ADC) at any point during your treatment.
You have received at least one round of treatment with either trastuzumab deruxtecan (T-DXd) and/or sacituzumab govitecan (SG), which are specific types of ADC drugs.

Who may not be able to join:

There are no specific exclusion criteria listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status

Completed

Phase

Not Applicable

Sponsor

Hellenic Cooperative Oncology Group

Registry

clinicaltrials_gov

Start date

1 January 2023

Est. completion

1 June 2024

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

The primary endpoint was toxicity rate of each drug

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov